Somewhat Negative Media Coverage Somewhat Unlikely to Affect ESSA Pharma (EPIX) Share Price
Headlines about ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) have been trending somewhat negative on Sunday, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ESSA Pharma earned a media sentiment score of -0.06 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.5193282169304 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
ESSA Pharma (NASDAQ EPIX) traded down $0.01 during trading hours on Friday, hitting $0.25. The company had a trading volume of 11,310 shares, compared to its average volume of 93,312. The company has a debt-to-equity ratio of -3.00, a current ratio of 2.32 and a quick ratio of 2.32. ESSA Pharma has a fifty-two week low of $0.24 and a fifty-two week high of $3.59.
A number of research firms recently weighed in on EPIX. Zacks Investment Research lowered ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, October 3rd. Bloom Burton lowered ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $4.75.
TRADEMARK VIOLATION WARNING: “Somewhat Negative Media Coverage Somewhat Unlikely to Affect ESSA Pharma (EPIX) Share Price” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/somewhat-negative-media-coverage-somewhat-unlikely-to-affect-essa-pharma-epix-share-price-2/1756288.html.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.